Composition and apparatus for transdermal delivery

• US 20050106209A1
• Filed: 10/21/2004
• Published: 05/19/2005
• Est. Priority Date: 11/13/2003
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Cormier, Michel, Maa, Yuh-Fun, Ameri, Mahmoud
• Application Number:
  US10/970,890
• Publication Number:
  US 20050106209A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61B 17/205 Vaccinating by means of needles or other puncturing devices
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/785 Polymers containing nitrogen
• CPC Class Codes: A61K 38/09 Luteinising hormone-releasing hormone [LHRH] , i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
• CPC Class Codes: A61K 38/095 Oxytocins; Vasopressins; Related peptides
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61K 38/2066 IL-10
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: A61K 38/215 IFN-beta
• CPC Class Codes: A61K 38/217 IFN-gamma
• CPC Class Codes: A61K 38/23 Calcitonins
• CPC Class Codes: A61K 38/24 Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
• CPC Class Codes: A61K 38/25 Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/29 Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
• CPC Class Codes: A61K 38/35 Corticotropin [ACTH]
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61M 37/0015 by using microneedles
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A formulation for coating a transdermal delivery device having a plurality of stratum corneum-piercing microprojections, the formulation including a biologically active agent and at least one viscosity-enhancing counterion. Preferably, the formulation has a viscosity in the range of about 20-200 cp.

Claims

1. A composition for coating a transdermal delivery device having stratum corneum-piercing microprojections comprising a formulation of a biologically active agent and a viscosity-enhancing counterion, wherein said formulation has a therapeutically effective concentration of said biologically active agent.

2. The composition of claim 1, wherein said formulation has a viscosity in the range of about 20 cp to about 200 cp.

3. The composition of claim 1, wherein said formulation has a first pH value, wherein said biologically active agent has a positive charge at said formulation pH, and wherein said viscosity-enhancing counterion comprises a first acid.

4. The composition of claim 3, wherein said first acid has at least two acidic pKa values.

5. The composition of claim 4, wherein said first acid is selected from the group consisting of maleic acid, malic acid, malonic acid, tartaric acid, adipic acid, citraconic acid, fumaric acid, glutaric acid, itaconic acid, meglutol, mesaconic acid, succinic acid, citramalic acid, tartronic acid, citric acid, tricarballylic acid, ethylenediaminetetraacetic acid, carbonic acid, sulfuric acid, and phosphoric acid.

6. The composition of claim 3, wherein said viscosity-enhancing counterion further includes a second acid.

7. The composition of claim 6, wherein said second acid has at least one acidic pKa value.

8. The composition of claim 7, wherein said second acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, nitric acid, sulfonic acid, sulfuric acid, maleic acid, phosphoric acid, benzene sulfonic acid, methane sulfonic acid, citric acid, succinic acid, glycolic acid, gluconic acid, glucuronic acid, lactic acid, malic acid, pyruvic acid, tartaric acid, tartronic acid, fumaric acid, acetic acid, propionic acid, pentanoic acid, carbonic acid, malonic acid, adipic acid, citraconic acid, levulinic acid, glutaric acid, itaconic acid, meglutol, mesaconic acid, citramalic acid, citric acid, tricarballylic acid and ethylenediaminetetraacetic acid.

9. The composition of claim 1, wherein said formulation has a second pH value, wherein said biologically active agent has a negative charge at said formulation second pH value, and wherein said viscosity-enhancing counterion comprises a first base.

10. The composition of claim 9, wherein said first base has at least two basic pKa values.

11. The composition of claim 10, wherein said first base is selected from the group consisting of lysine, histidine, arginine, calcium hydroxide and magnesium hydroxide.

12. The composition of claim 9, wherein said viscosity-enhancing counterion further includes a second base.

13. The composition of claim 12, wherein said second base has at least one basic pKa value.

14. The composition of claim 13, wherein said second base is selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, monoethanolomine, diethanolamine, triethanolamine, tromethamine, lysine, histidine, arginine, methylglucamine, glucosamine, ammonia, and morpholine.

15. The composition of claim 1, comprising an amount of said viscosity-enhancing counterion sufficient to neutralize a charge of said biologically active agent.

16. The composition of claim 1, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, goserelin, leuprolide, buserelin, triptorelin, other LHRH analogs, PTH, PTH (1-34), vasopressin, deamino [val4, D-Arg8] arginine vasopressin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM-CSF, G-CSF, IL-10, glucagon, GRF, analogs thereof and pharmaceutically acceptable salts thereof.

17. The composition of claim 16, wherein said viscosity-enhancing counterion comprises one or more acids selected from the group consisting of citric acid, tartaric acid, malic acid, hydrochloric acid, glycolic acid, and acetic acid.

18. The composition of claim 17, wherein said biologically active agent comprises PTH (1-34).

19. An apparatus for transdermally delivering a biologically active agent to a subject, comprising a microprojection member having a plurality of microprojections that are adapted to pierce said subjects stratum corneum, said microprojection member including a biocompatible coating having at least one biologically active agent, wherein said coating is formed from a formulation having at least one viscosity-enhancing counterion.

20. The apparatus of claim 19, wherein said formulation has a viscosity in the range of about of about 20-200 cp.

21. The apparatus of claim 19, wherein said biocompatible coating has a coating thickness less than about 10 microns.

22. The apparatus of claim 19, wherein said formulation has a first pH value and said biologically active agent has a positive charge at said formulation first value.

23. The apparatus of claim 22, wherein said formulation includes a first viscosity-enhancing counterion having at least two acidic pKa values.

24. The apparatus of claim 23, wherein said formulation includes a second viscosity-enhancing counterion, said second viscosity-enhancing counterion having at least one acidic pKa value.

25. The apparatus of claim 19, wherein said formulation has a second pH value and said biologically active agent has a negative charge at said formulation second pH value.

26. The apparatus of claim 25, wherein said formulation includes a first viscosity-enhancing counterion having at least two basic pKa values.

27. The apparatus of claim 26, wherein said formulation includes a second viscosity-enhancing counterion, said second viscosity-enhancing counterion having at least one basic pKa value.

28. The apparatus of claim 23, wherein said first viscosity-enhancing counterion has sufficient activity to neutralize a charge of said biologically active agent.